Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ: CMPS )

4.390 -0.020 (-0.45%)
Streaming Delayed Price Updated: 9:56 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
28 29 Next >
Psychedelic Stock Gainers And Losers From December 23, 2022
Via Benzinga
Cybin, ATAI Life Sciences Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From December 21, 2022
Via Benzinga
GH Research, Seelos Therapeutics Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From December 19, 2022
Via Benzinga
Major Psychedelic Drug Stocks Down Another 7% This Week; Now Down 54% YTD
The 6 largest psychedelic stocks that research the treatment of a variety of mental illnesses based on the use of 10 different psychedelic substances are down again this week. 
Via Talk Markets
Seelos Therapeutics, Mind Medicine Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From December 13, 2022
Via Benzinga
Psychedelic Stock Gainers And Losers From December 9, 2022
Via Benzinga
Psychedelic Stock Gainers And Losers From December 7, 2022
Via Benzinga
EXCLUSIVE: The Psychedelics Debate Is 'Raging' As Filament Debuts Ayahuasca Pill
Part two of a three-part series. Previous story: Standardized Ayahuasca Pill Is Officially Here, Feast Yourself With The Exclusive Details & Insights 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 16, 2022
Via Benzinga
Seelos Therapeutics, Cybin Among Top Psychedelic Movers Of Today
Via Benzinga
Psyched: Psychedelic Therapy In The Workplace, UCL's Brain Imaging Study, COMPASS Trials And More
Psychedelic Therapy Now Available As Workplace Benefit, Free Month For Laid-Off Tech Workers 
Via Benzinga
Psychedelic Stock Gainers And Losers From December 12, 2022
Via Benzinga
Magic Mushrooms Tested For Treating Type II Bipolar Disorder, Check Out Results So Far
Mental health care company COMPASS Pathways plc (NASDAQ: CMPS) has announced positive data demonstrating the potential of its proprietary synthetic psilocybin compound COMP360 in treating depression... 
Via Benzinga
Major Psychedelic Drug Stocks DOWN 9% Last Week; Now Down 51% YTD
Today's article highlights the performance of the largest psychedelic stocks that research the treatment of a variety of mental illnesses based on the use of ten (10) different psychedelic substances. 
Via Talk Markets
Colorado's Psychedelics Legal Scenario: Insurance & State Aid, Advisory Board And Local Regulations
Part three of three-part series.  See previous stories:  Colorado's New Psychedelics Regulations: Co-Author Of The Bill Replies To Concerns 
Via Benzinga
Psychedelics And Treatment-Resistant Depression: COMPASS Pathways Replies To Comments
(Part four of a four-part series) See previous stories:  
Via Benzinga
Compass Pathways, Mind Medicine Among Top Psychedelic Movers Of Today
Via Benzinga
Chefs' Warehouse, Chart Industries And Some Other Big Stocks Moving Lower On Thursday
U.S. stocks traded higher, with the Dow Jones jumping over 200 points on Thursday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Seelos Therapeutics, Numinus Wellness Among Top Psychedelic Movers Of Today
Via Benzinga
Seelos Therapeutics, GH Research Among Top Psychedelic Movers Of Today
Via Benzinga
Major Psychedelic Drug Stocks Went Up 7% This Week; Still Down 46% YTD
The 6 major psychedelic stocks researching the treatment of a variety of mental illnesses were UP 7% this week and are UP 3 % in the last 6 weeks. The 6 therapy clinic stocks went UP 3% this week and... 
Via Talk Markets
Psychedelic Stock Gainers And Losers From December 2, 2022
Via Benzinga
Psychedelic Stock Gainers And Losers From December 1, 2022
Via Benzinga
Psychedelic Stock Gainers And Losers From November 30, 2022
Via Benzinga
Revive Therapeutics, Seelos Therapeutics Among Top Psychedelic Movers Of Today
Via Benzinga
Psyched: Full-Dose & Microdosing LSD Studies, Research Scope For Fed Funding, Consumption Sites And More
LSD Research Ramps Up: Full-Dose & Microdosing For Alzheimer's Studies Led By Beckley Foundation Coming Soon 
Via Benzinga
3 Big Trends Shaking Up Psychedelic Stocks
Major positive shifts are happening, but the field faces new headwinds too. 
Via The Motley Fool
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
28 29 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.